MyMD Pharmaceuticals Inc (MYMD) Quote

8K filed by MYMD April 15, 2024, Adam Kaplan, Chief Scientific Officer resigned.

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug

https://www.biospace.com/article/releases/telomir-pharmaceuticals-unveils-compelling-pre-clinical-data-on-age-reversal-drug-telomir-1-at-national-press-club-event-in-washington-d-c-/

Question: Is Telomir-1 the successor of MYMD-1, discovered by the same people, who are now running Telomir Pharmaceuticals?

Have MYMD investors been totally abandoned while the best discoveries have been homed in a new company?

An unpleasant question to ask. I hope to be proven wrong.

I have been monitoring the pattern of MYMD stocks performance for the past 3 years.... They have bear group/Black pool internal group under Chairman Silverman who does reduce the stock during all good news intentionally. They dont want the fruits to go to investors buy all of their internal known group of people. Whatever happened reflects 100% manipulation like "star scientific" & Rock creek Pharma repetition.

My understannding is that: The 62M stocks reduced to 2.1M and now they want to add/dilute this again upto 62M stocks (12M Common & 50M Preferred Stock) in future by selling to various investors. Its all BIG manipulation.

I think it's more smoke and mirrors. (Hope I'm wrong). They sure do a great job of creating the impression they are serious... too much flash 'n fluff... However, we need something concrete other than promises, allusions, and illusions. Completed studies with attendant full reports noting clear & significant findings which either lead to partnerships or to market would help!!

From the 8-K just filed: https://ir.mymd.com/sec-filings/all-sec-filings##document-1028-0001493152-24-013870-1

Bio of Dr. Mitchell Glass (from https://www.medproinvestors.com/team; out of date probably)

Dr. Mitchell Glass is a 25 year veteran of the pharmaceutical industry.
His experience includes senior positions at top ten pharmaceutical companies,
as well as investment in and management of start-ups and biotechs.
 
After seven years of research, teaching and patient care at the University of Pennsylvania, Dr. Glass joined ICI Pharmaceuticals in 1988 where he established the pulmonary therapeutics group and led the development and submission of the antileukotriene ACCOLATE®. From 1995 to 1996, Dr. Glass was Vice President and Director at SmithKline Beecham where he was responsible for cardiovascular, respiratory, renal and metabolic drug development and commercialization, including submission of the NDA/MAA for COREG®. From 1998 to 2003, Dr. Glass was Chief Medical Officer and VP of Clinical Development and Regulatory Affairs of AtheroGenics Inc. (AGIX), where he led product development from IND to initiation of Phase 3 for AGI1067 and was a member of the IPO team. Dr. Glass later joined AQUMEN Biopharmaceuticals KK and NA as CEO of AQUMEN NA and currently serves as Executive VP R&D and Chief Medical Officer of Invion Limited. Dr. Glass graduated from the University of Chicago and is board certified in internal medicine, pulmonary and critical care medicine.

***

I have no idea what any of this 8-K signifies. Maybe tells us some preferred stock can be converted to common on terms specified in subsidiary documents.

The primary target for Telomir -- age reversal -- just so happens to align with MYMD's primary target of sarcopenia. Coincidence? I haven't been able to see the actual makeup of Telomir-1 but, like you, I suspect its development is directly linked to the research done for MYMD-1. Why haven't the full results from the sarcopenia study (which ended early June 2023) been published yet? The Annual Report just came out the other day and it does not inspire confidence. Actually, from what I can make of it, it looks quite disappointing... especially with the departure of key individuals. In addition, the lack of communication from the company is disturbing, and in light of everything else, rather alarming.

For those of us who were invested in Williams' previous ventures (i.e. Star Scientific, Rock Creek), this behavior of questionable actions (to say the least) unfortunately appears to be his M.O. He found a compelling means of raising significant capital and then leaving investors dry. I don't have a good feeling about any of it. It is indeed very unfortunate, because the product(s) and the research behind them were truly promising and significant!

Previous msg posted twice. No idea why.

I've noticed that migration. I wonder if the Telomir drug is a direct descendent of MYMD-1. If so, it seems that it should have been kept in MYMD for the benefit of MYMD's investors. Is it the case that they came up with something of extraordinary potential and decided to move it out of MYMD, abandoning the investors there, and put it into a new company to benefit a new group of investors? I hope this is not what's going on, but in the absence of communication from the company we can have no idea.

MYMD under $3

Do you know if people on this board were involved in this Scheme?
Notice how they have disappeared !!!!


"The day one of Reverse merger of MYMD with AKERS, the MYMD stock started plummeting. If you carefully monitor the trends of MYMD Stock fluctuations its always down whether you see positive news or not. This continuous manipulation is for a reason... probably bankrupt MYMD and sell this company to a Big pharma for a few Billions. Jonnie did same with Star Scientific & Rock Creek pharma. He ditched millions of sincere investors. I clearly see that he will do one more reverse split to keep the investors away and bankrupt and then sell the company for a great price as it has cleared Phase-2."

The day one of Reverse merger of MYMD with AKERS, the MYMD stock started plummeting. If you carefully monitor the trends of MYMD Stock fluctuations its always down whether you see positive news or not. This continuous manipulation is for a reason... probably bankrupt MYMD and sell this company to a Big pharma for a few Billions. Jonnie did same with Star Scientific & Rock Creek pharma. He ditched millions of sincere investors. I clearly see that he will do one more reverse split to keep the investors away and bankrupt and then sell the company for a great price as it has cleared Phase-2...

Anyone care to share their thoughts on this? It appears that Chris Chapman and Adam Kaplin have key roles in two more of Jonnie's new ventures: MIRA Pharma and Telomir Pharma. Until very recently Adam Kaplin was President and Chief Scientific Officer of MIRA Pharmaceuticals while Chapman was their CEO & Chairman of the Board. Now they are both gone from MIRA (or have greatly reduced roles) and have taken up new positions at Telomir

My question is: what about MYMD?? How can anyone expect to have any confidence in them or in the company when they do something like this?? Shouldn't they be devoting their time and energies to advancing the research and interests of MYMD?Is this even ethical? No wonder why the share value has been and is plummeting! Is this just another one of Jonnie's schemes? What do you all think?

"Hopefully, Williams gets it right this time." Not this time................

30 for 1 Reverse Split is not a positive event. All investors are under water.

Please remain under your rock and refrain from your annoying nonsense.

Williams is one of the worse business men on the planet.

MYMD new 52 week low

Pathetic !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Williams strikes again

MYMD: effective Feb. 15,2024 a one for 30 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

check this out.. about MyMD founder

https://www.newsweek.com/2014/01/24/funny-money-man-behind-mcdonnells-fall-245100.html

I have been telling in this board to all since many months that.... The Chairman of the Board Josh Silverman came from AKERS who is expert inn manipulation of the stocks... Now 30:1 reverse split will happen tomorrow, which reduces to shares 2,091,638. Important to note that, they already got approval from NASDAQ to add upto 16M new stocks if needed. This so called manipulators MyMD Founder Johnnie W, & Silverman add those remaining shares in short time which dilutes the value by saying Phase 3 purposes. This company is living on all frauds. What do you say?

Reverse split. 30 to 1.

Nasdaq Delisting of MYMD Notice as expected by Many sincere investors:
.
https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=317802932&type=HTML&symbol=MYMD&cdn=d11231e10863bcbb58b0c4d4615e2222&companyName=MyMD+Pharmaceuticals+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2023-10-13

I hope they find a partner because the hacks at the SEC might not be able to distinguish a naked short from a flasher. Just my humble opinion.

Not until the sec sends the naked short to prison or the company finds a partner. It’s a zero or 100+ dollar stock Make your bet at least I know my downside

New low at $ .165 on HUGE volume Will the selling ever end?

Canadian patent 3013634 granted

Abstract: "In one aspect, a method of increasing hair growth includes administering to an individual in need thereof a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable vehicle therefor. In another aspect, a method of improving the appearance of hair includes administering to an individual in need thereof a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor."

isomyosmine (MYMD-1) is interestingly versatile.

Near the close the price went as high as 0.21 on over 3,200,000 shares, then collapsed to 0.17 on much lower volume, closing at 0.203. After hours 0.18 seems to be popular. Hair raising, if you care. I don't much. This announcement means little, far as I can tell.

New 52 week low on huge volume--down trend continues

I don't know about Ray Blanco's current list. Read something by him many months ago. He was right then, and still right now about the science. But badly wrong about a good time to buy.

Nice to see someone that remembers Anatabloc…I too found it useful. Would be great if isomyosmine was “next generation”. I had seen that Ray Blanco was covering MYMD while it was still a $2 stock, but I had not seen it covered more recently…at least in the publications I had a subscription to. He still has it on a current list?

"If approved, MYMD-1 could become the first FDA-approved drug for sarcopenia, which causes patients to have a decline in muscle mass, among other symptoms.

MyMD Pharmaceuticals has already submitted and been approved for three Investigational New Drug Applications for MYMD-1. The company is advancing these clinical programs in chronic inflammatory conditions, including sarcopenia, rheumatoid arthritis and Hashimoto's disease, an often genetic disorder that causes inflammation of the thyroid gland.

$MYMD: WOAAAAahhhhhhhhhhhh whatta pop. now $0.30


That was a big suprise from 0.22

NICEEEEEEEEeeeeeeeeeeeeeee



GO $MYMD

Solid News https://www.accesswire.com/820920/mymd-pharmaceuticals-releases-positive-clinical-trial-results-for-sarcopenia-treatment-drug

Buy out.... ?

I don't agree. My friends, employees, and I had direct experience with Anatabloc, a product of William's Star Scientific. The anatabine-citrate molecule was the real thing. The benefits were remarkable. People homebound with Crohn's disease were set free.

Now, there is evidence that the isomyosmine molecule, MYMD-1, is an improvement on anatabine-citrate.

The article linked should be treated with suspicion as a possible "hit piece". There were political currents involving Bob McDonnell's race for governor of Virginia. Williams got swept up in those currents and a letter was issued by the FDA (trust them? no) that destroyed his company and injured McDonnell.

The molecule being developed by Williams and his collaborators at Johns Hopkins is both a threat and an opportunity for major pharma companies currently earning large revenues from the sale of biologics.

MYMD-1 does everything the leading biologics (Enbrel, Humira) do, but better and without the serious side effects. They are biological sledge hammers, MYMD-1 is a jewelers hammer.

Ray Blanco's assessment is correct.

How many times how many message boards you going to post the same thing. I will add tomorrow Thanking you

This article must be read by every one.. Please share this.
This is not the first time Jonnie is doing this kind of fraud, its almost 4th time ... same kind, with same Chris Chapman...From Starscientific to Rockcreek Pharma to MyMD Pharma... Jonnie manipulated (with some crooks like Silveman) all these stocks into Penny stocks. He will never change and he is living on innocent investors blood. Very unethical, inhumane.... Its nothing but unpardonable financial crime if any investigation takes palce. Please note...

https://www.newsweek.com/2014/01/24/funny-money-man-behind-mcdonnells-fall-245100.html

Take any profits you can by close tomorrow (best by close today). I believe shorts are closing and taking end year profits. Something to consider. Other thoughts for over 10M shares trading in less than 2 days, let's hear it.

Perhaps the buyout is taking place ..... this is well worth over $1 minimum ..... continuation into tomorrow?

Going crazy after hours. Last trade 0.43. Huge volume.

I'm inclined to agree.

Nice dream!!!

I haven’t, Is that what ur hearing

Has anyone heard about rumored Amgen buyout of MYMD?

Science Direct article about isomyosmine, 2019

A four year old article about the molecule that is MYMD-1

https://www.sciencedirect.com/science/article/abs/pii/S0165572819302206

Abstract

Multiple sclerosis (MS) is an autoimmune disease that remains in need of effective therapies. Plant-derived medicines have appealing properties for the treatment of autoimmune diseases. MYMD-1 is a synthetic plant alkaloid that has been shown to ameliorate the course of autoimmune thyroiditis. The goal of the present study was to determine whether MYMD-1 would produce similar beneficial effects in a mouse model of MS, experimental autoimmune encephalomyelitis (EAE) induced by immunization with myelin oligodendrocyte glycoprotein. MYMD-1 improved the course of EAE and suppressed activation of effector T cells without causing global immunosuppression or toxicity. These results suggest that MYMD-1 may be of interest for evaluating for the treatment of autoimmune diseases.

Jonnie R Williams, MyMD: A patent of astonishing range just allowed

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20220339147

In paragraph [0012] note the breadth of coverage - far beyond "visual system"

Patent Application Publication ao) Pub. No.: US 2022/0339147 Al
Williams Pub. Date: Oct. 27,2022

METHOD OF TREATING DISEASES OF THE VISUAL SYSTEM

SUMMARY

[0009] In some aspects, a method of regulating oxidoreductase activity for treating an inflammation or age-related disorder comprises administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor. In some examples, the inflammation-related disorder is a parasitic infection or disease such as malaria. In other examples, the inflammation-related disorder is a bacterial infection or disease such as Lyme disease.

[0010] In other examples, a method of treating oxidative stress associated with an inflammation or age-related disor­der comprises administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof, and a pharmaceu­tically acceptable vehicle therefor.

[0011] In yet other examples, a method of reducing oxi­dative stress in an individual suffering from an inflammation or age-related disorder comprises administering to the indi­vidual a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.

[0012] In other aspects, a method of treating a disorder comprises administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof, where the disorder is selected from the group consisting of infectious or parasitic diseases; neoplasms; diseases of the blood or blood-forming organs; diseases of the immune system; endocrine; nutri­tional or metabolic diseases; mental, behavioral or neurodevelopmental disorders; sleep-wake disorders; diseases of the nervous system; diseases of the visual system; diseases of the ear or mastoid process; diseases of the circulatory system; diseases of the respiratory system; diseases of the digestive system; diseases of the skin; diseases of the musculoskeletal system or connective tissue; diseases of the genitourinary system; conditions related to sexual health; pregnancy, childbirth or the puerperium; conditions origi­nating in the perinatal period; developmental anomalies; and injury ,poisoning or other consequences of external causes. In one example, a behavioral or neurodevelopmental disor­der is anxiety. In another example, a behavioral or neurode­velopmental disorder is depression.

***

A closely related patent:
Patent Application Publication (io)Pub. No.: US 2020/0338061 Al

Jonnie R Williams Pub.Date: Oct. 29,2020

METHODS OF REGULATING OXIDOREDUCTASE ACTIVITY FOR
TREATMENT OF INFLAMMATION AND AGE-RELATED DISORDERS

Applicant: MyMD Pharmaceuticals, Inc., Tampa, FL (US)

Another day another new low on HUGE volume.

Just amazing the selling volume as new lows are hit. Makes one wonder who is selling and why?

Entirely accidental. Making minor edits. I intended one post. Hub decided to make two posts. No idea why.